Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meitheal Looks To Chinese Parent To Bring In Three US Insulin Biosimilars

Licensee Tonghua Dongbao Pharmaceutical Expects Clinical Trials In 2024

Executive Summary

Designed as its US commercial arm following a major investment four years ago, Chinese player Nanjing King-Friend Biochemical Pharmaceutical has signed a deal allowing Meitheal Pharmaceuticals to sell three insulin biosimilars in the US.

You may also be interested in...



Meitheal Prepares For Major US Injectables Push

Meitheal Pharmaceuticals says it is preparing to launch “up to 20 new products” this year in the US following a recent expansion of its generic injectables portfolio.

US Aspart Filing Kicks Off Amphastar’s Insulin Ambitions

Amphastar says a “milestone” submission of a US filing for insulin aspart underlines its ambitions in the diabetes segment. But could the firm get the first US biosimilar approval?

Biocon Eyes 'Foothold To Stronghold' For (b)Humira In US, Pauses RH-Insulin Program

Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel